Abstract
After a roller coaster of conjecture, cancer drugmaker Seagen has finally been acquired. Pfizer agreed March 13 to buy the firm, formerly Seattle Genetics, for $43 billion. The deal is expected to be completed in late 2023 or early 2024. Seagen specializes in antibody-drug conjugates (ADCs), which link disease-fighting molecules to tumor cell–targeting antibodies. The goal of ADCs is to deliver powerful therapies specifically to tumor cells, sparing healthy cells from collateral damage. “Oncology is a core therapeutic area for Pfizer, and we believe the proposed combination with Seagen will enhance our position in this important space while significantly advancing the global fight against cancer,” Pfizer CEO Albert Bourla said in a March 13 call to discuss the deal with analysts and investors. He also emphasized the opportunity to combine Pfizer’s and Seagen’s assets into new therapeutic regimens, citing Seagen’s breast cancer drug Tukysa and Pfizer’s multiple myeloma drug candidate
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
